NL301043I2 - Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat - Google Patents
Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat Download PDFInfo
- Publication number
- NL301043I2 NL301043I2 NL301043C NL301043C NL301043I2 NL 301043 I2 NL301043 I2 NL 301043I2 NL 301043 C NL301043 C NL 301043C NL 301043 C NL301043 C NL 301043C NL 301043 I2 NL301043 I2 NL 301043I2
- Authority
- NL
- Netherlands
- Prior art keywords
- osilodrostat
- optionally
- pharmaceutically acceptable
- acceptable salt
- dihydrogen phosphate
- Prior art date
Links
- USUZGMWDZDXMDG-CYBMUJFWSA-N 4-[(5r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CC1 USUZGMWDZDXMDG-CYBMUJFWSA-N 0.000 title 2
- 229950009981 osilodrostat Drugs 0.000 title 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29498010P | 2010-01-14 | 2010-01-14 | |
| PCT/US2011/021100 WO2011088188A1 (en) | 2010-01-14 | 2011-01-13 | Use of an adrenal hormone-modifying agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301043I1 NL301043I1 (nl) | 2020-06-17 |
| NL301043I2 true NL301043I2 (nl) | 2020-07-06 |
Family
ID=43735742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301043C NL301043I2 (nl) | 2010-01-14 | 2020-06-10 | Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8609862B2 (nl) |
| EP (2) | EP2523731B1 (nl) |
| JP (4) | JP5602250B2 (nl) |
| KR (1) | KR101412206B1 (nl) |
| CN (2) | CN102711916B (nl) |
| AU (1) | AU2011205290C1 (nl) |
| BR (1) | BR112012017458B1 (nl) |
| CA (1) | CA2786443C (nl) |
| CL (1) | CL2012001961A1 (nl) |
| CY (2) | CY1121320T1 (nl) |
| DK (1) | DK2523731T3 (nl) |
| ES (1) | ES2707596T3 (nl) |
| HR (1) | HRP20190064T1 (nl) |
| HU (2) | HUE041967T2 (nl) |
| IL (1) | IL220804A0 (nl) |
| LT (2) | LT2523731T (nl) |
| LU (1) | LUC00159I2 (nl) |
| MA (1) | MA33904B1 (nl) |
| ME (1) | ME03371B (nl) |
| MX (2) | MX2012008212A (nl) |
| NL (1) | NL301043I2 (nl) |
| NO (1) | NO2020012I1 (nl) |
| NZ (1) | NZ601077A (nl) |
| PL (1) | PL2523731T3 (nl) |
| PT (1) | PT2523731T (nl) |
| RS (1) | RS58234B1 (nl) |
| RU (1) | RU2598708C2 (nl) |
| SG (1) | SG182393A1 (nl) |
| SI (1) | SI2523731T1 (nl) |
| TN (1) | TN2012000352A1 (nl) |
| TR (1) | TR201900515T4 (nl) |
| WO (1) | WO2011088188A1 (nl) |
| ZA (1) | ZA201205058B (nl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101412206B1 (ko) * | 2010-01-14 | 2014-06-25 | 노파르티스 아게 | 부신 호르몬 조절제의 용도 |
| US9078886B2 (en) | 2010-06-16 | 2015-07-14 | Embera Neurotherapeutics, Inc. | Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| AR086665A1 (es) | 2011-06-14 | 2014-01-15 | Lilly Co Eli | Inhibidor de aldosterona sintasa y composiciones farmaceuticas |
| EP2757884B1 (en) | 2011-09-22 | 2022-07-27 | Merck Sharp & Dohme LLC | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| EP2757883B1 (en) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| EP2757882B1 (en) | 2011-09-22 | 2020-11-04 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| UA114803C2 (uk) * | 2012-01-17 | 2017-08-10 | Новартіс Аг | ФОРМИ І СОЛІ ДИГІДРОПІРОЛ[1,2-c]ІМІДАЗОЛІЛЬНОГО ІНГІБІТОРА АЛЬДОСТЕРОНСИНТАЗИ АБО АРОМАТАЗИ |
| AU2013246908B2 (en) * | 2012-04-12 | 2016-06-30 | Novartis Ag | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
| CA2886117C (en) | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
| JP2015093832A (ja) * | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
| US10143680B2 (en) | 2014-07-07 | 2018-12-04 | Novartis Ag | Pharmaceutical dosage forms |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| PT3250555T (pt) | 2015-01-29 | 2021-04-27 | Recordati Ag | Processo para a produção de derivados de imidazolo condensado |
| US20160287565A1 (en) | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| JP2018518524A (ja) * | 2015-06-22 | 2018-07-12 | エンベラ ニューロセラピューティクス，インコーポレイティド | 物質使用障害、依存症及び精神障害の治療のための組成物及び方法 |
| CA3055940A1 (en) | 2017-03-10 | 2018-09-13 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4814333A (en) | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| US5658881A (en) | 1994-10-14 | 1997-08-19 | Twk, Inc. | Method for topical inhibition of the metabolic activity of cytochrome P450 |
| DE19814087A1 (de) | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
| US7417038B1 (en) | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
| ES2275853T3 (es) | 2001-02-16 | 2007-06-16 | Aventis Pharmaceuticals Inc. | Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3. |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| JP5138875B2 (ja) | 2005-07-19 | 2013-02-06 | 株式会社デンソー | センサ装置 |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| WO2007105203A2 (en) | 2006-03-16 | 2007-09-20 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| BRPI0712557A2 (pt) | 2006-05-26 | 2013-07-02 | Novartis Ag | inibidores de aldosterona sintase e/ou 11 beta-hidrolase |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| CA2660701A1 (en) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| EP2121652A1 (en) * | 2006-12-18 | 2009-11-25 | Novartis AG | 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |
| EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| KR101412206B1 (ko) * | 2010-01-14 | 2014-06-25 | 노파르티스 아게 | 부신 호르몬 조절제의 용도 |
| UA114803C2 (uk) * | 2012-01-17 | 2017-08-10 | Новартіс Аг | ФОРМИ І СОЛІ ДИГІДРОПІРОЛ[1,2-c]ІМІДАЗОЛІЛЬНОГО ІНГІБІТОРА АЛЬДОСТЕРОНСИНТАЗИ АБО АРОМАТАЗИ |
| AU2013246908B2 (en) * | 2012-04-12 | 2016-06-30 | Novartis Ag | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
-
2011
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Application Filing
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en active Application Filing
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 RU RU2012134510/15A patent/RU2598708C2/ru active
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
-
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
-
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
-
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
-
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
-
2019
- 2019-01-09 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
-
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301043I2 (nl) | Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat | |
| NL301238I2 (nl) | Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301006I2 (nl) | Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301041I2 (nl) | Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan | |
| NL300980I1 (nl) | Doravirine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301157I2 (nl) | odevixibat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301245I2 (nl) | Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301161I2 (nl) | zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301047I2 (nl) | fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride | |
| NL301155I2 (nl) | abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301191I2 (nl) | voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan | |
| NL300909I2 (nl) | Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301067I2 (nl) | Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat | |
| NL301119I2 (nl) | Selinexor of een farmaceutisch aanvaardbaar zout ervan | |
| NL301021I2 (nl) | talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| NL301131I2 (nl) | pemigatinib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301248I2 (nl) | atogepant of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301276I2 (nl) | omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300971I2 (nl) | Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301149I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL300901I2 (nl) | pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301284I2 (nl) | Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine | |
| NL301084I2 (nl) | remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan | |
| NL301234I2 (nl) | maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride | |
| NL301201I2 (nl) | Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride |